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Background: Brain-derived neurotrophic factor (BDNF) has an essential role in synaptic 
plasticity and neurogenesis. BDNF mediates amygdala-dependent learning for both aversive 
and appetitive emotional memories. The expression of BDNF in limbic regions is posited to 
contribute the development of depression, and amygdala responsivity is a potential marker 
of depressive state.  
Methods: The present study examined the relationship between platelet BDNF levels and 
amygdala volume and function in major depressive disorder (MDD). Participants were 23 
MDD (mean age 38.9 years) and 23 healthy controls (mean age 38.8 years). All participants 
were recruited from the community. MDD participants were in a current depressive episode 
of moderate severity and medication-free. Amygdala responses were acquired during a 
functional MRI task of implicit emotional processing with sad facial expressions.  
Results: Significant correlation was observed between platelet BDNF levels and left 
amygdala responses, but no significant correlations were found with right amygdala 
responses or with amygdala volumes.  
Limitations: Interactions with neuroprotective as well as neurotoxic metabolites in the 
kyneurenine pathway were not examined. 
Conclusions: Relationship between BDNF levels and amygdala responsivity to emotionally 
salient stimuli in MDD could reflect the importance of BDNF in amygdala-dependent learning 
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Introduction 
 
BDNF protein has an essential role in synaptic plasticity, neurogenesis and neuronal 
differentiation. BDNF crosses the blood brain barrier, and levels in the central nervous 
system are highly correlated with peripheral serum BDNF (Karege et al., 2002), which are 
interrelated with platelet BDNF (Serra-Millàs, 2016). Reduced serum and platelet BDNF 
levels have been observed in major depressive disorder (MDD), and the neurotrophin model 
proposes that stress decreases the expression of BDNF in limbic regions contributing to the 
development of depression (Duman and Monteggia, 2006; Serra-Millàs, 2016). 
 
Amygdala responsivity is a potential marker of depressive state which shows a 
demonstrated specificity to sad faces with increased activation during a current depressive 
episode that normalises following treatment (Fu et al., 2004; Arnone et al., 2015). The 
synaptic plasticity which underlies amygdala-dependent learning for both aversive and 
appetitive emotional memories is proposed to be mediated by BDNF (Heldt et al., 2014). 
BDNF is distributed within key regions in the neural circuitry of affective processing, in which 
the relationship between BDNF levels and amygdala structure and function offers a putative 
mechanism for regional brain alterations in MDD.  
 
Serum BDNF levels have been positively correlated with bilateral amygdala volumes in 
adolescents with bipolar disorder (Inal-Emiroglu et al., 2015) as well as with left amygdala 
volume in healthy adults over 60 years old (Manna et al., 2015). In a mouse model, chronic 
unpredictable mild stress was associated with increased BDNF expression in the amygdala 
and reduced resting state blood oxygenation level-dependent (BOLD) activity (Huang et al., 
2018). In individuals with combined MDD and anxiety disorders, however, no significant 
correlations were observed (van Velzen et al., 2016), although the sample may have been 
confounded by comorbid anxiety disorders and concomitant medications.  
 
The majority of peripheral BDNF is contained within platelets, which correlates with serum 
BDNF, and platelet-derived BDNF avoids confounds associated with serum BDNF, such as 
sex and ethnicity mediated by platelet count (Sera-Millàs et al., 2016). The present study 
sought to examine the relationship between platelet BDNF levels and amygdala volume and 
function in MDD during an unmedicated, current depressive episode. If BDNF is necessary 
for the consolidation of emotionally salient events (Heldt et al., 2014), then increased BDNF 






Cambridgeshire 4 NHS Research Ethics Committee, NHS Health Research Authority, 
provided ethical approval. All participants provided informed written consent. All participants 
were recruited from the general community (Fu et al., 2015). MDD participants met criteria 
defined by Diagnostic Statistical Manual of Mental Disorders, Fourth edition, text revision 
(DSM-IV-TR) (APA, 200). All MDD participants had first episode or recurrent MDD, in a 
current depressive episode, at least moderate severity as measured by a minimum score of 
18 on 17-item Hamilton Rating Scale for Depression (HRSD). All were free of antidepressant 
or psychotherapy treatment for a minimum of 4 weeks, or 6 weeks for fluoxetine.  Exclusion 
criteria included comorbid Axis I or II disorders and treatment-resistant depression. Healthy 
participants had no history of medical or psychiatric disorders. Histories were confirmed from 
general practitioner records. 
 
Blood sample and BDNF analysis 
 
The blood sample was obtained on the day of the magnetic resonance imaging (MRI) scan, 
by Vacutainer serum tubes, processed and stored at -80 oC. Platelets were thawed on ice, 
centrifuged, and the pellet was reconstituted in ice cold TME buffer (10mM Tris HCl;  1mM 
MgCl; 1mM EDTA pH 7.5) and protease inhibitor cocktail (Sigma Aldrich #P2714).  Pellet 
was homogenized with 20 strokes of a hand held, teflon/glass homogenizer. Homogenate 
was centrifuged 40.000xg for 30 minutes.  Supernatant  was collected, and protein 
determination performed using Bradford  assay.  BDNF was assayed from the supernatant 
using 100ul of 1mg/mL of each sample in each well of the ELISA (Millipore, CYT306). The 




MRI data acquisition  
 
High-resolution 3-dimensional sagittal T1-weighted structural images (Magnetization 
Prepared Rapid Gradient Echo; resolution 1 mm3) and gradient echo T2*-weighted 
echoplanar images depicting blood oxygenation level-dependent (BOLD) contrast were 
acquired. Total of 180 volumes, consisting of 39 oblique axial slices parallel to the 
intercommissural plane with parameters: slice thickness: 3 mm, slice gap: 0.3 mm, echo 
time: 30 milliseconds, repetition time: 2000 milliseconds, flip angle: 75°, field of view: 240 
mm, and matrix size: 64 × 64 for each volume.  
 
In the functional MRI scan, participants viewed a series of 10 faces (5 female), adapted from 
Ekman and Friesen’s Pictures of Facial Affect morphed to depict varying intensities of 
sadness: low, medium and high. Participants indicated the gender by button press, with the 
explicit instruction being gender identification to facilitate implicit emotion processing 
(Costafreda et al., 2008). Facial stimuli were presented twice at each intensity, 60 faces in 
total, with 12 baseline trials, consisting of a crosshair, for total of 72 presentations in a 
pseudo-randomised order. Each stimulus was presented for 3 s, and the interval between 
trials varied randomly according to a Poisson distribution, with mean intertrial interval of 5 s, 
for a total duration of 360 s.  
 
MRI data analysis 
 
Analysis of structural images was performed with Freesurfer 4.5.0 automated longitudinal 
stream to obtain amygdala volumes. Quality control was performed by visually assessing the 
brain segmentation overlaid on original T1 image to ensure that cortical reconstructions did 
not present major anomalies. Medial temporal lobe region was assessed with coronal 
sections. All reconstructions passed qualitative control, and original Freesurfer outputs were 
used without manual corrections.  
 
Left and right amygdalae regions of interest were defined according to Harvard-Oxford 
probability atlas distributed with FMRIB Software Library (FSL) package 
(http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/Atlases). Statistical Parametric Mapping (SPM8, Wellcome 
Department of Imaging Neuroscience, London, UK: http://www.fil.ion.ucl.ac.uk/spm) was 
used to pre-process and analyse functional MRI data. Images were realigned to correct for 
motion artefacts, spatially normalized to the Montreal Neurological Institute (MNI) template, 
and smoothed using an 8 mm full-width at half maximum (FWHM) Gaussian kernel filter. 
First-level analysis was performed using general linear model, accounting for serial 
autocorrelations by applying an autoregressive model. Stimuli presentation was modelled as 
individual events, and the first level analysis produced contrast images depicting overall 
facial processing capacity (mean difference in response between all facial trials taken 
together and baseline trials). Region of interest analysis was performed using MarsBar tool 
in SPM8 (http://marsbar.sourceforge.net/). BOLD responses for left and right amygdalae 




A Pearson’s bivariate correlation analysis with BDNF levels was performed for left and right 
amygdalae separately, using the stats package in R statistical software (R Foundation for 




Participants were 23 MDD (10 women), mean age 38.9 (standard deviation (SD) 12.1) years 
and 23 age and IQ matched healthy controls, mean age 38.8 (SD 10.2) years, from African, 
Asian and Caucasian ethnicities (Table 1). Mean platelet BDNF levels were 89.8 (SD 56.8) 
ng/mL in MDD and 83.1 (SD 52.7) ng/mL in healthy control participants (Table 1). In MDD, 
the correlation between left amygdala BOLD response and BDNF levels was statistically 
significant (r = 0.42, p = 0.043) (Figure 1). The correlation remained significant when BOLD 
response was normalised by left amygdala volume (r = 0.45, p = 0.031). There were no 
significant associations between BDNF levels and right amygdala BOLD response (r = 0.07, 
p = 0.756) or with amygdala volumes (left amygdala, r = - 0.11, p = 0.605; right amygdala, r 




Amygdala response was significantly correlated with platelet BDNF levels in a community 
sample of MDD participants who were unmedicated in a current depressive episode and 
who did not have treatment-resistant depression. No relationship was found between BDNF 
levels and amygdala volumes, consistent with the lack of associations in participants with 
MDD which had been comorbid with anxiety disorders (van Velzen et al., 2016). BDNF 
signalling is integral for amygdala-dependent learning (Heldt et al., 2014), and the present 
findings support a role for BDNF in amygdala responsivity in MDD. 
 
BDNF has a critical role in synaptic plasticity, neural growth, differentiation and maintenance. 
A common single nucleotide functional polymorphism in the BDNF gene which results in a 
valine to methionine (Val66Met) substitution has been associated with reduced BDNF 
secretion, and BDNF Val66Met genotype modulates amygdala responsivity (Egan et al., 
2003). The BDNF 66Met allele has demonstrated a specific association with increased 
amygdala activation to emotional faces in adolescents with MDD or anxiety disorders which 
was not observed in healthy adolescents (Lau et al., 2010). In adults, the BDNF 66Met allele 
has been associated with persistently elevated amygdala activation to repeated 
presentations of unpleasant pictures, representing an impairment in habituation, in 
borderline personality disorder (Perez-Rodriguez et al., 2017).  
 
The pathway from the Val66Met genotype to BDNF gene expression to BDNF protein may 
be modulated by BDNF methylation which shows an inverse correlation with BDNF levels 
(Kleimann et al., 2015). DNA methylation is an epigenetic mechanism whereby gene 
expression can be altered, and peripheral blood cell BDNF methylation has been associated 
with MDD (Fuchikami et al., 2011). Neural plasticity in the amygdala is dependent on BDNF, 
and BDNF is essential for the consolidation of both appetitive and aversive learning (Heldt et 
al., 2014). Sad facial expressions are emotionally salient stimuli for a current depressive 
episode in MDD, and increased BDNF levels were associated with increased amygdala 
BOLD responses. Aversive learning increases the probability of amygdala activation 
(Costafreda et al., 2008). While present task instructions did not explicitly involve learning, 
the inherent acquisition of associations with the emotionally salient stimuli could have 
sufficiently engaged amygdala nuclei. The potential as a clinical state marker or prognostic 
marker though would depend on its sensitivity and specificity at the individual level. 
 
Left hemispheric lateralisation of amygdala responsivity has been reported in MDD to sad 
fearful and neutral faces expressions that were supraliminally as well as subliminally 
presented (Korgaonker et al., 2018). In healthy individuals, left lateralization of amygdala 
activation is significantly associated with language-based tasks, in which there is a greater 
reduction in the probability of activation in right amygdala activation (Costafreda et al., 2008). 
The usual perceptual bias for aversive relative to neutral words is absent with left or bilateral 
amygdala lesions but not with right amygdala lesions (Anderson and Phelps, 2001). 
Lateralisation of the relationship between BDNF levels with the left amygdala has been 
reported in amygdala volume in healthy adults who were 60-76 years, but not in younger 
cohorts (Manna et al., 2015). We did not find any significant associations with BDNF levels 
and amygdala volumes in the present sample, which had excluded participants who were 
over the age of 60 years. 
 
Limitations include the strength of correlation which may be considered to be moderate and 
that correlation does not indicate causation in which additional mediating factors could be 
implicated, such as the relationship between BDNF and the kynurenine pathway. Activation 
of the kynurenine pathway is proposed to partly mediate the effects of inflammatory 
processes that lead to the development of depression. The kynurenine pathway consists of 
putative neurotoxic as well as neuroprotective metabolites which impact on N-methyl-D-
aspartate (NMDA) receptors and glutamatergic neurotransmission. NMDA is associated with 
decreased secretion of BDNF, and an inverse relationship has been observed between 
BDNF and the neurotoxic metabolite 3-hydroxy-kynurenine (3-HK). Levels of kynurenine and 
its neuroprotective metabolite kynurenic acid (KYNA) are reduced in depression, which 
shows increased synthesis along with diminished production of the neurotoxic 3-HK 
metabolite in astroglial cultures following 24 hour incubation with antidepressant medication 
(Kocki et al., 2012). Kynurenine and KYNA levels are positively correlated with amygdala 
volume in MDD (Savitz et al., 2015).  
 
In summary, a significant positive correlation was evident between platelet BDNF levels and 
amygdala activation in participants with recurrent MDD during a current depressive episode 
that was unmedicated. The relationship between BDNF levels and amygdala responsivity to 
emotionally salient stimuli in MDD could reflect the importance of BDNF in amygdala-
dependent learning with clinical implications for treatment pathways. Interactions with the 
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Total number  23 23 
Number female participants 10 10 
Mean age (years) 38.9 (12.1) 38.8 (10.2) 
Ethnicity:   
African  3 8 
Asian 9 3 
Caucasian 11 12 
HRSD 21.8 (0.3) 0.3 (1.1) 
Verbal IQ 110.42 (10.33) 110.00 (12.6) 
Mean platelet BDNF (ng/mL) 89.8 (56.8) 83.1 (52.7) 
Right amygdala volume (mm3) 1705.00 (245.65) 1697.30 (165.64) 
Left amygdala volume (mm3) 1697.30 (24.93) 1491.91 (170.67) 
 
Data presented as mean and standard deviation in parenthesis. HRSD=Hamilton Rating 
Scale for Depression. There were no significant differences in Verbal IQ (p=0.91), BDNF 









Scatter plot and correlation between platelet BDNF levels (ng/mL) and left amygdala BOLD 
response in MDD and healthy control participants. There was a significant correlation 
between platelet BDNF levels and left amygdala BOLD response in MDD (r = 0.42, p = 
0.043) (black circles), but not in healthy control participants (grey circles).  
 
  
Figure 1. 
 
 
 
  
 
